← Eichor
Study identifier: NCT05951777 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Condition: Traumatic Brain Injury  ·  Sponsor: Hope Biosciences LLC

PhasePhase 2
Planned participants51
Who can joinAll sexes, 18 Years to 55 Years
Healthy volunteersNo

About this study

The global objective of this study is to establish the safety and investigate the potential treatment effect of an intravenous infusion of HB-adMSCs (Hope Biosciences adipose-derived mesenchymal stem cells) on brain structure, neurocognitive/functional outcomes, and neuroinflammation after traumatic brain injury.

This description comes directly from the study's public registry record.

Talk to the study team

Carmen Duron, RN, MHA, BSN  ·  713-500-7395  ·  Maria.Carmen.Duron@uth.tmc.edu

Carla Mendoza, BSN, RN  ·  713-500-8206  ·  Carla.D.Wilkerson@uth.tmc.edu

Always discuss trial participation with your own doctor first.

Locations (2)

Memorial Hermann Hospital / UTHealth McGovern Medical School at HoustonHouston, Texas, United StatesRecruiting
The University of Texas Health Science at San AntonioSan Antonio, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05951777